The results demonstrated that TMED3 expression levels significantly affected patient survival, with GBM patients exhibiting higher TMED3 expression showing markedly reduced overall survival (OS) and disease-free survival (DFS) in comparison to individuals with low TMED3 expression (Fig. 1b, c). This evidence concerns the gene TMED3 and glioblastoma.